Trials / Recruiting
RecruitingNCT06615050
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 572 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tacrolimus (Tac) | Tablet or intravenously (IV) |
| DRUG | Methotrexate (MTX) | Intravenously (IV) |
| DRUG | Ruxolitinib (Rux) | Tablet |
| DRUG | Cyclophosphamide | Intravenously (IV) |
| DRUG | Mycophenolate mofetil (MMF) | Tablet or intravenously (IV) |
Timeline
- Start date
- 2025-04-02
- Primary completion
- 2031-01-17
- Completion
- 2031-01-17
- First posted
- 2024-09-26
- Last updated
- 2026-04-16
Locations
30 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06615050. Inclusion in this directory is not an endorsement.